US Stock Insider Trading | Xencor Disclosed 7 Company Insider Transactions on March 9

K-LinePoet · 2026-03-15T16:14:21+00:00

# Xencor Discloses 7 insider Trades on March 9, 2026Xencor disclosed 7 insider trades on March 9, 2026. Director Dahiyat Bassil I sold a total of 21,600 shares on March 5 and 6, while other executives also conducted multiple stock sales. Xencor is a company focused on developing innovative biologics.

K-LinePoet

2026-03-15 16:14:21

Abstract generation in progress

On March 9, 2026, Xencor (XNCR) disclosed seven insider trading transactions. Director Dahiyat Bassil I sold 14,900 shares on March 5, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 9, 2026	Executive	Eckert Celia	March 6, 2026	Sell	1,767	11.02	$19,500
March 9, 2026	Executive	Cornelissen Bart Jan	March 5, 2026	Sell	2,517	11.25	$28,300
March 9, 2026	Executive	Desjarlais John R	March 5, 2026	Sell	4,118	11.25	$46,300
March 9, 2026	Director	Dahiyat Bassil I	March 5, 2026	Sell	14,900	11.25	$167,200
March 9, 2026	Executive	Desjarlais John R	March 6, 2026	Sell	2,502	11.02	$27,600
March 9, 2026	Executive	Eckert Celia	March 5, 2026	Sell	3,244	11.25	$36,500
March 9, 2026	Director	Dahiyat Bassil I	March 6, 2026	Sell	6,606	11.02	$72,800
March 4, 2026	Executive	Desjarlais John R	March 3, 2026	Sell	2,663	11.90	$31,700
March 4, 2026	Director	Dahiyat Bassil I	March 3, 2026	Sell	6,758	11.90	$80,400
March 4, 2026	Executive	Eckert Celia	March 3, 2026	Sell	1,492	11.90	$17,700

[Company Profile]

Xencor, Inc. was founded in California in August 1997 and reorganized in Delaware in September 2004. The company is a clinical-stage biopharmaceutical firm focused on discovering and developing engineered monoclonal antibodies and cytokine therapies to treat cancer and autoimmune diseases where unmet medical needs exist. The company leverages protein engineering capabilities to enhance understanding of protein structures and interactions, designing new technologies and XmAb candidate drugs with improved properties.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes